Hydrea
ApprovedSmall molecule
Hydrea is one of 73 small molecule programs targeting Sickle Cell Disease. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
72
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
272 competitors in Sickle Cell Disease
#DrugCompanyPhaseTrials
1Exjade
NovartisPhase 3
Brilinta
AstraZenecaPhase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Ritalin
NovartisPhase 3
Cysteine Hydrochloride
NovartisPhase 3
Eliquis
Bristol-Myers SquibbPhase 3
Oxbryta
GGlobal Blood Therapeutics
Phase 3
Aqvesme
AAgios Pharmaceuticals, Inc.
Phase 3
Effient
CCosette Pharmaceuticals, Inc.
Phase 3
Xarelto
WWim Janssens
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hydrea. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details